US Bancorp DE Lowers Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

US Bancorp DE decreased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 34.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,896 shares of the company’s stock after selling 983 shares during the period. US Bancorp DE’s holdings in Apellis Pharmaceuticals were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. nVerses Capital LLC grew its position in shares of Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 1,300.8% in the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock valued at $211,000 after purchasing an additional 3,330 shares during the last quarter. CWM LLC raised its stake in shares of Apellis Pharmaceuticals by 299.9% in the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after acquiring an additional 3,113 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares in the last quarter. Finally, Tidal Investments LLC acquired a new stake in shares of Apellis Pharmaceuticals in the first quarter valued at $266,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This represents a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Trading Down 6.4 %

Shares of APLS opened at $26.27 on Monday. The stock has a market cap of $3.27 billion, a PE ratio of -12.94 and a beta of 0.87. The stock’s 50-day moving average is $29.93 and its two-hundred day moving average is $36.25. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $73.80. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue for the quarter was up 78.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.17) earnings per share. Equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on APLS shares. Citigroup decreased their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company lowered their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. William Blair began coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating for the company. Oppenheimer reduced their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, UBS Group decreased their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.06.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).